Sandra J. Strauss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sandra J. Strauss has a total of 392 co-authors. Here are the top co-authors by number of shared publications:
- Nathalie Gaspar
Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
10 shared publications - Jeremy Whelan
Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom
6 shared publications - Katrina M. Ingley
Sarcoma Department, University College London Hospital, London NW1 2PB, UK
6 shared publications - Martin Gerard McCabe
The Christie NHS Foundation Trust, Manchester, UK
6 shared publications - Emanuela Palmerini
Osteoncology, Soft Tissue and Bone Sarcomas, Innovative Therapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
5 shared publications - Rachael Windsor
Children and Young People’s Cancer Service, University College London Hospitals NHS Foundation Trust, London, UK
5 shared publications
Latest Publications
- 4 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations
PURPOSE: Ewing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2 , TP53 , and CDKN2A ) and copy-number variants. Currently, diagnosis relies exclusively on tumor biopsies and imaging, and despite a well-defined genomic landscape, risk stratification remains based solely on clinicoradiologic parameters. Furthermore, tumor evolution and intrapatient heterogeneity remain poorly characterized, and prospective evidence supporting molecular risk stratification is limited. MATERIALS AND METHODS: We prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, complemented by relapse studies. Across 347 patients, 991 blood, tumor, and bone marrow samples were profiled using custom targeted sequencing and shallow whole-genome sequencing to enable integrated biologic characterization and clinical correlative analyses. RESULTS: ctDNA recapitulated established Ewing sarcoma genomic landscapes while also revealing intrapatient tumor heterogeneity when compared with matched tumor biopsy profiles. Blood and bone marrow plasma profiles were highly concordant. Longitudinal sampling identified selection of TP53 -altered clones at relapse. Clinically, detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA at diagnosis predicted poor outcomes and, in a multivariable model adjusting for metastatic status, tumor volume, age, and treatment, defined an independent molecular high-risk subgroup with inferior event-free survival (hazard ratio [HR], 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) in EE2012 patients. CONCLUSION: Prospective, trial-integrated ctDNA profiling provides comprehensive molecular characterization, reveals clinically relevant heterogeneity and clonal evolution, and identifies an independent molecular high-risk subgroup at diagnosis, supporting ctDNA-guided risk stratification in Ewing sarcoma.
- 4 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations
PURPOSE: Ewing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2 , TP53 , and CDKN2A ) and copy-number variants. Currently, diagnosis relies exclusively on tumor biopsies and imaging, and despite a well-defined genomic landscape, risk stratification remains based solely on clinicoradiologic parameters. Furthermore, tumor evolution and intrapatient heterogeneity remain poorly characterized, and prospective evidence supporting molecular risk stratification is limited. MATERIALS AND METHODS: We prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, complemented by relapse studies. Across 347 patients, 991 blood, tumor, and bone marrow samples were profiled using custom targeted sequencing and shallow whole-genome sequencing to enable integrated biologic characterization and clinical correlative analyses. RESULTS: ctDNA recapitulated established Ewing sarcoma genomic landscapes while also revealing intrapatient tumor heterogeneity when compared with matched tumor biopsy profiles. Blood and bone marrow plasma profiles were highly concordant. Longitudinal sampling identified selection of TP53 -altered clones at relapse. Clinically, detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA at diagnosis predicted poor outcomes and, in a multivariable model adjusting for metastatic status, tumor volume, age, and treatment, defined an independent molecular high-risk subgroup with inferior event-free survival (hazard ratio [HR], 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) in EE2012 patients. CONCLUSION: Prospective, trial-integrated ctDNA profiling provides comprehensive molecular characterization, reveals clinically relevant heterogeneity and clonal evolution, and identifies an independent molecular high-risk subgroup at diagnosis, supporting ctDNA-guided risk stratification in Ewing sarcoma.
- Open Access
Oncolytic virus-antibody combinations enhance immune-mediated killing of osteosarcoma
A major barrier to effective immunotherapy in osteosarcoma (OS) is the highly immunosuppressive tumour microenvironment (TME), which limits immune recognition and elimination of tumour cells. We evaluated a panel of oncolytic herpes simplex viruses (oHSVs) for their direct oncolytic activity, immune‑modulatory properties and capacity to counteract OS‑associated immunosuppression using immunologically relevant in vitro models. We demonstrate that established OS cell lines, primary cell cultures and dissociated OS cells from freshly resected tumour samples are susceptible to direct oncolysis by three oHSVs; HSV1716, HSV1716‑GMCSF, and HSV47Δ, although susceptibility levels varied. Treatment of peripheral blood mononuclear cells from healthy donors and OS patients with oHSVs enhanced natural killer (NK) cell activation and promoted immune‑mediated killing of OS cell lines and primary OS cell cultures. Among the three viruses, HSV1716‑GMCSF exhibited the strongest immune‑stimulatory effects and was uniquely capable of reducing the abundance of CD163+CD206+ immunosuppressive TAMs; use of this oHSV was therefore prioritised. We developed a multicellular spheroid model of OS, incorporating OS cells, mesenchymal stem cells and TAMs, which exhibits resistance to immune-mediated killing, better reflecting the immunosuppressive TME in patients. In this model, pairing HSV1716‑GMCSF treatment with either anti‑GD2 or anti‑EGFR monoclonal antibodies (mAbs), selected according to OS tumour antigen expression, significantly increased immune‑mediated tumour cell killing. These findings suggest that personalised combination strategies pairing oHSVs with appropriate mAbs provide a promising therapeutic approach for OS by integrating direct oncolysis, remodelling of the immunosuppressive TME and enhanced immune‑mediated tumour destruction.
Open AccessOncolytic virus-antibody combinations enhance immune-mediated killing of osteosarcoma
A major barrier to effective immunotherapy in osteosarcoma (OS) is the highly immunosuppressive tumour microenvironment (TME), which limits immune recognition and elimination of tumour cells. We evaluated a panel of oncolytic herpes simplex viruses (oHSVs) for their direct oncolytic activity, immune‑modulatory properties and capacity to counteract OS‑associated immunosuppression using immunologically relevant in vitro models. We demonstrate that established OS cell lines, primary cell cultures and dissociated OS cells from freshly resected tumour samples are susceptible to direct oncolysis by three oHSVs; HSV1716, HSV1716‑GMCSF, and HSV47Δ, although susceptibility levels varied. Treatment of peripheral blood mononuclear cells from healthy donors and OS patients with oHSVs enhanced natural killer (NK) cell activation and promoted immune‑mediated killing of OS cell lines and primary OS cell cultures. Among the three viruses, HSV1716‑GMCSF exhibited the strongest immune‑stimulatory effects and was uniquely capable of reducing the abundance of CD163+CD206+ immunosuppressive TAMs; use of this oHSV was therefore prioritised. We developed a multicellular spheroid model of OS, incorporating OS cells, mesenchymal stem cells and TAMs, which exhibits resistance to immune-mediated killing, better reflecting the immunosuppressive TME in patients. In this model, pairing HSV1716‑GMCSF treatment with either anti‑GD2 or anti‑EGFR monoclonal antibodies (mAbs), selected according to OS tumour antigen expression, significantly increased immune‑mediated tumour cell killing. These findings suggest that personalised combination strategies pairing oHSVs with appropriate mAbs provide a promising therapeutic approach for OS by integrating direct oncolysis, remodelling of the immunosuppressive TME and enhanced immune‑mediated tumour destruction.
- 8 August 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 246, 116981
Incidence and survival of primary bone sarcoma diagnosed in England between 1996 and 2020; An analysis from the National Disease Registration Service
- 8 August 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 246, 116981
Incidence and survival of primary bone sarcoma diagnosed in England between 1996 and 2020; An analysis from the National Disease Registration Service
- 31 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study
PURPOSE: Euro-EWING99 study was a large, international, prospective study recruiting patients with Ewing sarcoma (EWS) between 1999 and 2015. It assessed three different clinical questions through randomized trials. We report here the characteristics and outcomes of all patients. METHODS: Patients younger than 50 years with EWS were included in the study. They received induction chemotherapy (six courses of vincristine [day 1], ifosfamide [day 1-3], doxorubicin [day 1-3], and etoposide [day 1-3; VIDE], administered every 3 weeks), local therapy (surgery/radiotherapy), and different consolidation treatments according to clinical risk group and trial. The objectives of the study were to describe the entire cohort according to the initial staging group, to describe the survival outcomes (overall survival [OS]; progression-free survival [PFS]; and local control), and to evaluate prognostic factors associated with OS and PFS. RESULTS: Three thousand three hundred ninety-five patients were included in the study, including 2,267 with a localized disease, 614 with pleuropulmonary metastases, and 514 with extrapulmonary metastases. Ninety-eight percent of patients received ≥4 neoadjuvant VIDE courses. The modalities of local treatment and consolidation therapy differed among the three staging groups. With a median follow-up of 7.2 years, PFS of the entire cohort was 60.2% and 55.4% at 3 and 5 years, respectively. OS was 72.6% and 64.6% at 3 and 5 years, respectively. In addition to metastatic status at diagnosis, main prognostic factors included patient age, tumor volume, and histologic response both for PFS and OS, independent of metastatic status. CONCLUSION: To our knowledge, this study is the largest published series of patients with EWS and may serve as a landmark paper for EWS. It confirms the major prognostic value of the complete histologic response after neoadjuvant therapy.
- 31 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study
PURPOSE: Euro-EWING99 study was a large, international, prospective study recruiting patients with Ewing sarcoma (EWS) between 1999 and 2015. It assessed three different clinical questions through randomized trials. We report here the characteristics and outcomes of all patients. METHODS: Patients younger than 50 years with EWS were included in the study. They received induction chemotherapy (six courses of vincristine [day 1], ifosfamide [day 1-3], doxorubicin [day 1-3], and etoposide [day 1-3; VIDE], administered every 3 weeks), local therapy (surgery/radiotherapy), and different consolidation treatments according to clinical risk group and trial. The objectives of the study were to describe the entire cohort according to the initial staging group, to describe the survival outcomes (overall survival [OS]; progression-free survival [PFS]; and local control), and to evaluate prognostic factors associated with OS and PFS. RESULTS: Three thousand three hundred ninety-five patients were included in the study, including 2,267 with a localized disease, 614 with pleuropulmonary metastases, and 514 with extrapulmonary metastases. Ninety-eight percent of patients received ≥4 neoadjuvant VIDE courses. The modalities of local treatment and consolidation therapy differed among the three staging groups. With a median follow-up of 7.2 years, PFS of the entire cohort was 60.2% and 55.4% at 3 and 5 years, respectively. OS was 72.6% and 64.6% at 3 and 5 years, respectively. In addition to metastatic status at diagnosis, main prognostic factors included patient age, tumor volume, and histologic response both for PFS and OS, independent of metastatic status. CONCLUSION: To our knowledge, this study is the largest published series of patients with EWS and may serve as a landmark paper for EWS. It confirms the major prognostic value of the complete histologic response after neoadjuvant therapy.
- 29 June 2026
- Published by Elsevier in The Lancet Oncology
- Vol. 27 (7) , e339-e349
European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine
- 29 June 2026
- Published by Elsevier in The Lancet Oncology
- Vol. 27 (7) , e339-e349
European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine
- Open Access
- 6 June 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Critical appraisal of patient-reported and clinician-reported outcome measures assessing functional outcomes in lower extremity bone sarcoma patients—a COSMIN-based systematic review
Purpose: Local therapy for bone sarcoma often significantly impacts patients’ physical abilities and participation in daily life, which underscores the need for accurate assessment of these outcomes to guide optimal care. This study aims to 1) evaluate the measurement properties of eight patient- and clinician-reported outcome measures identified in a recent systematic review (2024) as being used more than once in this population, and 2) recommend the most suitable instruments for evaluation in clinic and research. Methods: We searched MEDLINE and Embase in July 2024 for studies assessing the development and/or measurement properties of the original version of the Baeck equestionnaire, Functional Mobility Assessment, Karnofsky Performance Status, Mankin score, MusculoSkeletal Tumor Society 1987 and 1993-Lower extremity (LE)scores, Reintegration to Normal Living (RNL) Index and Toronto Extremity Salvage Score (TESS) – LE. Full text availability was required. Measurement instruments were evaluated using COSMIN guidelines (July 2024 – January 2025). Results: Seventy-three articles evaluating measurement properties of one of the eight instruments were included. The Baecke questionnaire, RNL Index and TESS-LE had clearly defined constructs of which only the RNL Index and TESS-LE demonstrated sufficient overall content validity (low- and moderate-quality evidence). The remaining instruments lacked clear construct definitions, resulting in indeterminate or insufficient content validity, and therefore cannot be recommended for use. Structural validity of the TESS-LE was inconsistent leading to indeterminate internal consistency, currently preventing its recommendation. Additionally, the evidence supporting sufficient measurement properties of the RNL Index was too limited to justify its use. Conclusion: A clearly defined construct is the cornerstone of a measurement instrument and was lacking in most cases. The TESS-LE and RNL Index show promise due to their sufficient content validity, but require further refinement before they can be recommended as standard instruments to assess physical abilities and participation in daily life in bone sarcoma patients. Advancing measurement of these outcomes requires comprehensive validation and refinement of existing instruments to overcome their current limitations, or the development of new, reliable, and valid instruments tailored to this population. Registration: Study protocol registration in the PROSPERO database:CRD42022353668.
- 6 June 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessCritical appraisal of patient-reported and clinician-reported outcome measures assessing functional outcomes in lower extremity bone sarcoma patients—a COSMIN-based systematic review
Purpose: Local therapy for bone sarcoma often significantly impacts patients’ physical abilities and participation in daily life, which underscores the need for accurate assessment of these outcomes to guide optimal care. This study aims to 1) evaluate the measurement properties of eight patient- and clinician-reported outcome measures identified in a recent systematic review (2024) as being used more than once in this population, and 2) recommend the most suitable instruments for evaluation in clinic and research. Methods: We searched MEDLINE and Embase in July 2024 for studies assessing the development and/or measurement properties of the original version of the Baeck equestionnaire, Functional Mobility Assessment, Karnofsky Performance Status, Mankin score, MusculoSkeletal Tumor Society 1987 and 1993-Lower extremity (LE)scores, Reintegration to Normal Living (RNL) Index and Toronto Extremity Salvage Score (TESS) – LE. Full text availability was required. Measurement instruments were evaluated using COSMIN guidelines (July 2024 – January 2025). Results: Seventy-three articles evaluating measurement properties of one of the eight instruments were included. The Baecke questionnaire, RNL Index and TESS-LE had clearly defined constructs of which only the RNL Index and TESS-LE demonstrated sufficient overall content validity (low- and moderate-quality evidence). The remaining instruments lacked clear construct definitions, resulting in indeterminate or insufficient content validity, and therefore cannot be recommended for use. Structural validity of the TESS-LE was inconsistent leading to indeterminate internal consistency, currently preventing its recommendation. Additionally, the evidence supporting sufficient measurement properties of the RNL Index was too limited to justify its use. Conclusion: A clearly defined construct is the cornerstone of a measurement instrument and was lacking in most cases. The TESS-LE and RNL Index show promise due to their sufficient content validity, but require further refinement before they can be recommended as standard instruments to assess physical abilities and participation in daily life in bone sarcoma patients. Advancing measurement of these outcomes requires comprehensive validation and refinement of existing instruments to overcome their current limitations, or the development of new, reliable, and valid instruments tailored to this population. Registration: Study protocol registration in the PROSPERO database:CRD42022353668.
- Open Access
Clinical Presentation and Tumour Burden in Head and Neck Sarcomas: Implications for Early Diagnosis and Referral
Background/Objectives: Head and neck sarcomas account for 11% of all soft tissue and 9% of all bone sarcomas in the UK. Diagnostic delays are common, with non-specific symptoms and histological misdiagnosis reported in up to 42% of cases. This study aims to evaluate the association between presenting symptoms, symptom duration, and tumour size to inform a tailored HNS diagnostic strategy for early referral to a tertiary centre. Methods: We analysed a retrospective cohort of 425 adult and paediatric patients referred to the London Sarcoma Service between 2002 and 2025. Results: Our cohort analysis identified a median tumour size of 44.00 mm and symptom duration of 3 months. Although symptom duration did not predict tumour size (β = 0.63, p = 0.76), non-specific symptoms (swelling, pain, nasal/oral changes) were significantly associated with larger tumours (OR 1.96–3.66), alongside systemic symptoms (β = 22.90 mm, p = 0.044). Each 1 mm increase in tumour size was also associated with a 2.60% increased chance of a higher-grade sarcoma (OR = 1.03 per mm, p < 0.001). Conclusions: To our knowledge, this is the largest cohort study to characterise diagnostic patterns in HNS. Our findings reveal three critical insights: 1. Current size-based referral thresholds are inadequate. 2. Non-specific symptoms, such as nasal or oral symptoms, are frequently overlooked. 3. The anatomical complexity of the HN region demands early tailored diagnostic strategies. We propose a hypothesis-generating ‘1–2–1’ framework to support earlier clinical suspicion, which requires prospective validation.
Open AccessClinical Presentation and Tumour Burden in Head and Neck Sarcomas: Implications for Early Diagnosis and Referral
Background/Objectives: Head and neck sarcomas account for 11% of all soft tissue and 9% of all bone sarcomas in the UK. Diagnostic delays are common, with non-specific symptoms and histological misdiagnosis reported in up to 42% of cases. This study aims to evaluate the association between presenting symptoms, symptom duration, and tumour size to inform a tailored HNS diagnostic strategy for early referral to a tertiary centre. Methods: We analysed a retrospective cohort of 425 adult and paediatric patients referred to the London Sarcoma Service between 2002 and 2025. Results: Our cohort analysis identified a median tumour size of 44.00 mm and symptom duration of 3 months. Although symptom duration did not predict tumour size (β = 0.63, p = 0.76), non-specific symptoms (swelling, pain, nasal/oral changes) were significantly associated with larger tumours (OR 1.96–3.66), alongside systemic symptoms (β = 22.90 mm, p = 0.044). Each 1 mm increase in tumour size was also associated with a 2.60% increased chance of a higher-grade sarcoma (OR = 1.03 per mm, p < 0.001). Conclusions: To our knowledge, this is the largest cohort study to characterise diagnostic patterns in HNS. Our findings reveal three critical insights: 1. Current size-based referral thresholds are inadequate. 2. Non-specific symptoms, such as nasal or oral symptoms, are frequently overlooked. 3. The anatomical complexity of the HN region demands early tailored diagnostic strategies. We propose a hypothesis-generating ‘1–2–1’ framework to support earlier clinical suspicion, which requires prospective validation.
- 29 July 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (7) , 1020-1028
Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review
The outcome of patients with osteosarcoma after relapse is very poor, with a 5-year overall survival (OS) below 30%. Prognostic factors in this setting remain poorly defined, limiting treatment decisions. This study identifies key clinical and biological prognostic factors to guide future trials. A systematic review and meta-analysis included studies published between 1976 and 2022 with ≥35 patients. Searches were performed in MEDLINE/PUBMED, EMBASE, and Cochrane. Study quality was assessed using QUIPS tool. Studies reporting any clinical outcomes in the post-relapse setting were included. Nineteen studies involving 3245 patients were analysed. Nine prognostic factors were identified: relapse-free interval, site, number and size of lesions, resectability, sex, age, alkaline phosphatase levels and response to chemotherapy. Meta-analysis confirmed bilateral lung metastases worsened OS (HR 1.68, 95% CI 1.42-1.99). A relapse-free interval >24 months and complete surgical resection were consistently associated with better outcomes. Results on chemotherapy use were inconsistent. Substantial heterogeneity and low methodological quality were noted across studies. Key prognostic factors should address clinical trial design. Stratification by resectability, number and site of lesions and relapse-free interval is essential to evaluate treatment efficacy. Standardised protocols are needed to improve outcomes and provide tailored strategies for relapsed osteosarcoma.
- 29 July 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (7) , 1020-1028
Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review
The outcome of patients with osteosarcoma after relapse is very poor, with a 5-year overall survival (OS) below 30%. Prognostic factors in this setting remain poorly defined, limiting treatment decisions. This study identifies key clinical and biological prognostic factors to guide future trials. A systematic review and meta-analysis included studies published between 1976 and 2022 with ≥35 patients. Searches were performed in MEDLINE/PUBMED, EMBASE, and Cochrane. Study quality was assessed using QUIPS tool. Studies reporting any clinical outcomes in the post-relapse setting were included. Nineteen studies involving 3245 patients were analysed. Nine prognostic factors were identified: relapse-free interval, site, number and size of lesions, resectability, sex, age, alkaline phosphatase levels and response to chemotherapy. Meta-analysis confirmed bilateral lung metastases worsened OS (HR 1.68, 95% CI 1.42-1.99). A relapse-free interval >24 months and complete surgical resection were consistently associated with better outcomes. Results on chemotherapy use were inconsistent. Substantial heterogeneity and low methodological quality were noted across studies. Key prognostic factors should address clinical trial design. Stratification by resectability, number and site of lesions and relapse-free interval is essential to evaluate treatment efficacy. Standardised protocols are needed to improve outcomes and provide tailored strategies for relapsed osteosarcoma.
- Open Access
- 16 July 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (14) , e71044
Prognostic Factors in Newly Diagnosed High‐Grade Osteosarcoma—A Systematic Review
Introduction: Pretreatment prognostic factors in newly diagnosed osteosarcoma are important for clinical management and stratifying patients in clinical trials. Such factors include the presence of metastases, primary tumor size, and site. Factors surrounded by controversy include pathological fracture, histologic subtype, and P‐glycoprotein expression. No prognostic tumor biomarker has been established. We performed a systematic review with the aim to compile available evidence for pretreatment prognostic factors and define optimal cut‐off values for patient stratification or further validation in the upcoming European FOSTER‐CabOS trial.Methods: Predefined search terms were used to search PubMed, Web‐of‐science, and Embase for all studies investigating pretreatment prognostic factors in newly diagnosed osteosarcoma patients published 2000–2023. After applying strict inclusion and exclusion criteria, 49 papers were included.Results: We found 14 factors investigated in at least two separate studies or in a single study using one discovery and at least one validation cohort.Conclusions: We confirmed the prognostic value of patient age, presence of metastasis, tumor size, and site (axial vs. appendicular). Future studies of these factors should focus on specific patient populations and defining optimal cut‐off values. Although serum level of alkaline phosphatase and lactate dehydrogenase were associated with outcome, it remains unclear if they are independent of other prognostic factors. The prognostic value remains unclear for sex, pathological fracture, histologic subtype, and P‐glycoprotein expression. We could not establish any new prognostic biomarker. However, circulating tumor DNA in plasma and the G1/G2 RNA signature in diagnostic tumor biopsies show promise and will be further validated in the upcoming FOSTER‐CabOS trial.
- 16 July 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (14) , e71044
Open AccessPrognostic Factors in Newly Diagnosed High‐Grade Osteosarcoma—A Systematic Review
Introduction: Pretreatment prognostic factors in newly diagnosed osteosarcoma are important for clinical management and stratifying patients in clinical trials. Such factors include the presence of metastases, primary tumor size, and site. Factors surrounded by controversy include pathological fracture, histologic subtype, and P‐glycoprotein expression. No prognostic tumor biomarker has been established. We performed a systematic review with the aim to compile available evidence for pretreatment prognostic factors and define optimal cut‐off values for patient stratification or further validation in the upcoming European FOSTER‐CabOS trial.Methods: Predefined search terms were used to search PubMed, Web‐of‐science, and Embase for all studies investigating pretreatment prognostic factors in newly diagnosed osteosarcoma patients published 2000–2023. After applying strict inclusion and exclusion criteria, 49 papers were included.Results: We found 14 factors investigated in at least two separate studies or in a single study using one discovery and at least one validation cohort.Conclusions: We confirmed the prognostic value of patient age, presence of metastasis, tumor size, and site (axial vs. appendicular). Future studies of these factors should focus on specific patient populations and defining optimal cut‐off values. Although serum level of alkaline phosphatase and lactate dehydrogenase were associated with outcome, it remains unclear if they are independent of other prognostic factors. The prognostic value remains unclear for sex, pathological fracture, histologic subtype, and P‐glycoprotein expression. We could not establish any new prognostic biomarker. However, circulating tumor DNA in plasma and the G1/G2 RNA signature in diagnostic tumor biopsies show promise and will be further validated in the upcoming FOSTER‐CabOS trial.